寡转移性骨病患者接受立体定向体部放疗后局部控制与生存改善相关的患者及治疗因素:大型单中心经验结果
该单中心研究分析了2011年3月至2020年6月连续接受骨立体定向体部放疗(SBRT)的434例患者,评估患者与治疗因素与局部控制(LC)、无进展生存(PFS)和总生存(OS)的关联。结果显示,寡转移(OM)病灶中BED10≥50与LC改善相关,非脊柱骨病灶中PTV≥150 cc与LC更差相关;前列腺组织学、PS 0-1、无转移间期≥2年及异时、同时或重复OM状态与PFS和OS改善相关。
要点
- OM病灶BED10≥50与LC改善相关(HR 0.68,95%CI 0.48-0.96,P<.03)。
- 非脊柱骨病灶PTV≥150 cc与LC更差相关(HR 1.94,95%CI 1.02-3.70,P<.04)。
- 前列腺组织学、PS 0-1、无转移间期≥2年及异时、同时或重复OM与PFS和OS改善相关。
关键数值与推荐
- OM病灶BED10≥50与LC改善相关(HR 0.68,95%CI 0.48-0.96,P<.03)。
- 非脊柱骨病灶PTV≥150 cc与LC更差相关(HR 1.94,95%CI 1.02-3.70,P<.04)。
- 前列腺组织学、PS 0-1、无转移间期≥2年预测PFS和OS改善(P<.05)。
- 异时、同时或重复OM较诱导性OM有更高的PFS和OS(P≤.001)。
临床怎么用
- 作者结论指出,OM病灶BED10≥50与非脊柱骨病灶PTV<150 cc与LC改善相关。
- 作者结论指出,前列腺组织学、PS 0-1、无转移间期≥2年及按ESTRO/EORTC标准的异时、同时或重复OM表现预测骨SBRT治疗的OM患者PFS和OS改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limited data exist to guide optimal patient selection and treatment of bone metastases with curative intent despite the increasing application of stereotactic body radiation therapy (SBRT) for oligometastatic (OM) disease control and reirradiation (Re-RT). METHODS AND MATERIALS: Clinical characteristics for 434 patients consecutively treated with bone SBRT at a single institution from March 2011 to June 2020 were analyzed by OM, spine, and nonspine bone using Cox regression to determine association with local control (LC), progression-free survival (PFS), and overall survival (OS), and the Kaplan-Meier method to estimate PFS and OS. RESULTS: Most patients had prostate (39%) or breast/lung (21%) cancer and 1 to 3 lesions (96%), with 651 lesions (spine 63%) treated for Re-RT (12%) or OMD (88%), including synchronous (10%), metachronous (28%), repeat (27%), or induced (23%) states as defined by The European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer criteria. Biologically effective dose (BED10) ≥50 (hazard ratio, 0.68; 95% confidence interval, 0.48-0.96; P < .03) predicted improved LC among OM lesions and planning target volume (PTV) ≥150 cc (hazard ratio, 1.94; 95% confidence interval, 1.02-3.70; P < .04) predicted worse LC for nonspine bone. Prostate histology, performance status (PS) 0 to 1, and metastasis-free interval ≥2 year predicted improved PFS and OS (P < .05). Metachronous, synchronous, or repeat OM had higher PFS and OS (P ≤ .001) than induced OM. With median follow-up 25.7 months, 1- and 2-year PFS was 63% and 47% for OM and 36% and 25% for Re-RT; 1- and 2-year OS was 87% and 73% for OM and 58% and 43% for Re-RT. Acute toxicities included grade 1 to 2 pain flare (9%) and fatigue (14%). Late toxicities included fracture (1%) for OM and myelopathy (2.5%) or nerve pain (1.2%) for Re-RT. CONCLUSIONS: BED10 ≥50 for OM and PTV <150 cc for nonspine bone lesions was associated with improved LC. Prostate histology, PS 0 to 1, metastasis-free interval ≥2 years, and metachronous, synchronous, or repeat presentations per The European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer criteria predicted improved PFS and OS among OM patients treated with bone SBRT.
引用
- Thomas MC, Chen YH, Fite E, et al. Patient and Treatment Factors Associated With Improved Local Control and Survival in Oligometastatic Bone Disease: Results From a Large Single-Institution Experience Using Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2022. PMID: 35840113. doi:10.1016/j.ijrobp.2022.06.096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。